South African scientific institutions and international partners are advancing a roadmap for African-led genomics research, aiming to use the continent’s extensive human genetic diversity to improve disease diagnosis, treatment and public-health outcomes. The initiative highlights the need for stronger research infrastructure, local scientific expertise, responsible genomic-data governance and sustained investment so African researchers can develop technologies that address African healthcare priorities.”
African Genomics Initiative Puts South African Biotechnology at the Centre of Future Healthcare
South Africa advances African-led biotechnology research
South Africa is strengthening its role in African biotechnology research as scientists, government representatives and international partners work to turn the continent’s extensive human genetic diversity into practical healthcare solutions. A high-level meeting held in Pretoria has placed genomics, research infrastructure, scientific capacity and African ownership of biological data at the centre of discussions about the future of public health.
The meeting took place from 7 to 9 October 2026 at the Council for Scientific and Industrial Research (CSIR) International Convention Centre. The International Centre for Genetic Engineering and Biotechnology (ICGEB) and CSIR convened the gathering in partnership with South Africa’s Department of Science, Technology and Innovation (DSTI). ICGEB published its report on 15 October.
The discussions focused on developing a roadmap for African-led genomics research, capacity-building and healthcare applications. The initiative reflects a broader scientific challenge: although Africa contains substantial human genetic diversity, African populations remain underrepresented in many international genomic databases.
This imbalance can limit researchers’ ability to understand inherited disease risks, interpret genetic test results and develop medical treatments suited to different populations.
For South Africa, the discussions represent an opportunity to strengthen local scientific capabilities while contributing to a wider African research agenda.
Why human genetic diversity matters
Genomics is the study of an organism’s complete genetic information. In human healthcare, it can help researchers investigate why individuals develop particular diseases, why patients respond differently to medicines and how genetic variations influence the effectiveness or safety of treatment.
Human populations possess different patterns of genetic variation shaped by ancestry, migration, population history and other factors. When research databases represent some populations far more extensively than others, scientific conclusions may not translate equally well across communities.
African populations are particularly important to genomic research because the continent contains exceptionally high human genetic diversity. Studying this diversity can help researchers identify biological relationships that might remain difficult to detect using datasets dominated by populations from other regions.
The Pretoria meeting therefore addressed more than the expansion of scientific knowledge. It considered how African researchers could use genomic information to improve diagnosis, treatment and health research while ensuring that African institutions help determine research priorities.
Potential applications include investigations into inherited disorders, cancer, sickle cell disease, pharmacogenomics and gene therapy. These fields may eventually support more accurate diagnoses, better-targeted treatments and improved understanding of disease across African populations.
However, genetic diversity does not automatically produce better healthcare. Real benefits require reliable laboratory methods, appropriate clinical studies, trained specialists, secure data systems and healthcare services capable of using the resulting evidence.
A roadmap for African scientific leadership
According to ICGEB, participants examined the current state of human genomics research in Africa and identified priorities for building the infrastructure needed to expand the field.
South Africa’s Minister of Science, Technology and Innovation, Professor Blade Nzimande, delivered a keynote address calling for Africa to participate fully in research agenda-setting, knowledge generation and technology development rather than serving primarily as a source of data.
This principle is important for the future of biotechnology. Scientific partnerships can provide access to funding, equipment and international expertise, but their long-term value also depends on whether African institutions develop the skills and capabilities to lead projects independently.
The meeting brought together representatives from research organisations, government, funding bodies and international institutions. Contributors included CSIR Chief Executive Officer Dr Thulani Dlamini, ICGEB Director-General Dr Lawrence Banks and South African Medical Research Council President and Chief Executive Officer Professor Ntobeko Ntusi.
The programme covered human genetics, pharmacogenomics, rare disorders, cancer genomics, sickle cell disease and gene therapy.
Participants discussed the infrastructure, computing resources, biobanks, ethical frameworks and regulatory systems required to support genomics research. These components are essential because modern genomic studies can involve large datasets, complex laboratory procedures and sensitive information about individuals and families.
The intended next step is the development of a roadmap for African-led genomics research, capacity and health applications, which will be presented to the minister and DSTI for further strategic discussions.
The roadmap’s eventual impact will depend on how its priorities are translated into funded programmes, institutional responsibilities and measurable outcomes.
Connecting biotechnology to better medical treatment
One of the most promising applications of genomics is pharmacogenomics, which examines how genetic differences influence the way people process and respond to medicines.
Patients can respond differently to the same medication. Genetic variation is one factor that can affect how a drug is metabolised, its effectiveness and the risk of certain adverse reactions. Other factors, including age, other medicines, nutrition and underlying illnesses, also influence treatment outcomes.
Research involving African populations could help generate evidence that is more representative of the patients treated by healthcare systems across the continent.
South Africa’s universities and research institutions are positioned to contribute through laboratory science, computational biology, clinical research and collaboration with healthcare professionals. Nevertheless, translating findings into routine medical practice requires additional validation, suitable diagnostic tests, clinical guidelines and professional training.
Genomics can also support investigations into inherited conditions and the biological mechanisms behind particular cancers. Researchers may use genetic information to identify relevant disease pathways, develop hypotheses and investigate potential therapeutic targets.
These approaches should not be confused with guaranteed cures or immediate changes in treatment. Most applications require extensive research and, where appropriate, clinical validation before they can be adopted safely.
The central opportunity is to establish research systems that produce evidence relevant to African populations and can ultimately inform clinical decisions.
Building the infrastructure biotechnology requires
Genomics research depends on more than advanced sequencing machines. Institutions also need trained laboratory personnel, bioinformaticians, computing infrastructure, secure storage, quality-control systems and reliable access to research funding.
Biobanks and biological sample collections can support research by providing carefully documented materials under appropriate ethical and legal safeguards. Their value depends on consent procedures, accurate records, secure handling and clear rules governing access and future use.
Computational capacity is equally important. Researchers must be able to process large datasets, compare genetic patterns, evaluate statistical results and protect sensitive information.
Investment in these capabilities could strengthen South Africa’s wider biotechnology ecosystem, supporting academic research, diagnostic development and potential partnerships with biotechnology companies.
Training is another priority. Universities and research organisations need opportunities to develop specialists in genomics, molecular biology, bioinformatics, clinical genetics and related disciplines. Building this expertise locally can reduce dependence on external institutions and enable African scientists to lead complex projects.
However, infrastructure investments must be sustainable. Equipment requires maintenance, laboratories need consistent supplies, and skilled researchers need long-term career opportunities. A successful roadmap will therefore need to consider operating costs and workforce retention alongside the purchase of technology.
Ethical governance and African ownership of data
Human genomic information raises significant ethical questions because genetic data can reveal sensitive information about individuals and their biological relatives.
Research participants need appropriate information about how their samples and data will be used, who may access them and whether they could be shared with other institutions. Consent, confidentiality, responsible data management and independent ethical review are important safeguards.
Cross-border collaboration adds further complexity. International partnerships can expand scientific opportunities, but participating institutions must establish clear arrangements for data access, research responsibilities and the sharing of benefits.
African ownership of research should therefore mean more than physically storing information within national borders. It should also involve meaningful participation in decision-making, scientific leadership, analytical capacity and the development of resulting technologies.
Equitable partnerships can help ensure that African institutions contribute to research design and interpretation rather than simply supplying samples or information for projects conducted elsewhere.
At the same time, appropriate data sharing remains important for scientific progress. The challenge is to develop governance arrangements that protect participants while allowing legitimate research to advance.
The Pretoria discussions placed these questions within a wider debate about scientific sovereignty and the need for African priorities to guide genomics research.
Funding and collaboration will determine progress
Developing a strong genomics ecosystem requires sustained financial support from governments, research funders, universities and responsible private-sector partners.
Funding must cover the entire research pathway, from basic science and sample collection to computational analysis, validation, clinical evaluation and the development of usable technologies.
Collaboration between institutions can help pool expertise and equipment, establish common research standards and support training. International partnerships may also create opportunities for African researchers to access specialist knowledge and participate in larger scientific programmes.
However, collaboration should produce durable local capacity rather than short-term activity alone. Clear goals, transparent funding arrangements and measurable results will be important in assessing whether the roadmap delivers lasting benefits.
South Africa’s role in convening research institutions and supporting regional cooperation could help connect scientific expertise across African countries. Success will depend on whether the proposed priorities lead to practical projects and sustained institutional commitments.
What the initiative means for South Africa
For South Africa, stronger genomics capacity could contribute to scientific development, medical research and innovation. Better understanding of genetic variation may eventually support improvements in diagnostics, treatment research and the interpretation of disease risks.
The initiative could also help strengthen links between universities, public research institutions, healthcare providers and biotechnology businesses.
Yet research advances alone cannot resolve every barrier to healthcare. Access to diagnostic services, affordability, trained clinical personnel and reliable health infrastructure remain essential if new technologies are to benefit patients.
Genomic testing must also be used appropriately. Genetic information does not determine every aspect of an individual’s health, and findings must be interpreted in context rather than treated as definitive predictions of disease.
The most meaningful measure of progress will therefore be whether research produces validated knowledge and practical tools that improve healthcare without increasing inequalities or compromising privacy.
Conclusion: Turning scientific ambition into public-health benefits
The Pretoria genomics meeting marks an important step in discussions about the future direction of African biotechnology. Its emphasis on African-led research, infrastructure, scientific training and responsible governance addresses several barriers that have limited the representation of African populations in genomic science.
South Africa’s institutions have an opportunity to help translate these priorities into collaborative research programmes that respond to local and regional health needs.
The next stage will require a clear roadmap, sustained investment, strong ethical safeguards and measurable progress towards developing locally led scientific capabilities.
Although better diagnosis and more personalised treatments remain long-term goals rather than guaranteed immediate outcomes, genomics offers substantial opportunities for research across Africa.
If the proposed roadmap leads to practical implementation, South Africa could strengthen its contribution to a biotechnology ecosystem in which African scientists generate knowledge, develop technologies and help shape the future of healthcare on the continent.
